RxDoctor Payments Data

Dalianne Rivera, MD

General Practice · Saint Cloud, FLNPI 1356870935

Payments from drug & device makers

$4,554in general payments, 2019–2025

Across 151 payments — averaging $30.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • Johnson & Johnson$246
  • Merck$210
  • Boehringer Ingelheim$206
  • Esperion Therapeutics, Inc.$201
  • plus $873 from 12 others

What the payments were for

  • Food & beverage$4,540100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,554 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$17,098
Medicare patients
42
Services billed
266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide351$465,792
JardianceEmpagliflozin212$227,645
EliquisApixaban126$115,725
FarxigaDapagliflozin Propanediol112$114,889
Trelegy ElliptaFluticasone/Umeclidin/Vilanter76$96,876
TrulicityDulaglutide48$95,946
ProliaDenosumab23$39,075
MounjaroTirzepatide24$30,419
LinzessLinaclotide39$29,333
Repatha SyringeEvolocumab17$23,705
XareltoRivaroxaban12$18,372
TradjentaLinagliptin11$16,355
EntrestoSacubitril/Valsartan14$15,120
VascepaIcosapent Ethyl25$15,007
Breo ElliptaFluticasone/Vilanterol19$12,806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,317$465,792351 claims
Boehringer IngelheimJardiance, Tradjenta$206$243,999223 claims
Lilly USA, LLCTrulicity, Mounjaro$183$126,36572 claims
AstraZenecaFarxiga, Symbicort$1,502$122,949136 claims
PfizerEliquis$172$115,725126 claims
GSKTrelegy Ellipta, Breo Ellipta$14$109,68395 claims
AmgenProlia$60$39,07523 claims
AbbVieLinzess$42$29,33339 claims
Johnson & JohnsonXarelto, Invokana$246$25,27424 claims
NovartisEntresto$15$15,12014 claims
BayerKerendia$116$9,99714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.

Other general practice in Saint Cloud

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →